Q3 2025 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2025-11-04 · accession 0001193125-25-263831
$260.4M
Reported value
9
Positions
2025-09-30
Period end
The Brief · Sanofi (SNY, SNYNF) · Q3 2025
AI · grounded in 13F
Sanofi SNY established a new position in MeiraGTx Holdings plc MGTX valued at $100.4M. The fund also initiated new stakes in Novavax NVAX for $59.7M and Inhibrx Biosciences, Inc. INBX for $39M. Additional new positions include AnaptysBio ANAB, Immuneering Corp IMRX, and Omada Health Inc. OMDA.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $100.4M | 38.6% | 12,197,737 | Common | SOLE |
| 670002401 | NVAX | Novavax | $59.7M | 22.9% | 6,880,481 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $39.0M | 15.0% | 1,157,926 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $25.2M | 9.67% | 821,917 | Common | SOLE |
| 45254E107 | IMRX | Immuneering Corp | $19.0M | 7.28% | 2,708,559 | Common | SOLE |
| 68170A108 | OMDA | Omada Health Inc. | $11.6M | 4.46% | 524,903 | Common | SOLE |
| N51517105 | 4PKB | LAVA Therapeutics N.V. | $3.0M | 1.15% | 1,919,455 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $2.1M | 0.81% | 814,980 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $483,284 | 0.19% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.